| Literature DB >> 30987780 |
Gladys Asong1, Xue Y Zhu1, Barbara Bricker1, Terrick Andey1, Felix Amissah1, Nazarius Lamango1, Seth Y Ablordeppey1.
Abstract
Our previous study has revealed 4-(4-(4-chlorophenyl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl)butan-1-one·2HCl (SYA013) 1 as a sigma ligand with moderate selectivity for the sigma-2 receptor. Given the overexpression of sigma receptors in solid tumors and reports of sigma ligands with anticancer activities, we selected 1 for evaluation in several solid tumor cell lines. In addition, we have synthesized new analogs of 1 and now report that several of them bind preferentially at the sigma-2 receptor and have shown inhibition of several cancer cell lines including MDA-MB-231, MDA-MB-486, A549, PC-3, MIA PaCa-2 and Panc-1 cells. In particular, compounds 1 and 12 have demonstrated sub-micromolar activity against the Panc-1 cell line. It has also been observed that several of these compounds demonstrate selective toxicity toward cancer cells, when compared to normal cells. Published by Elsevier Ltd.Entities:
Keywords: Anticancer activity; Homopiperazine; Indanone; Oxime; Sigma receptors; Sigma-2 receptor
Year: 2019 PMID: 30987780 PMCID: PMC6536312 DOI: 10.1016/j.bmc.2019.04.012
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641